Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 4.09% is 64% below its 5-year average of 11.30%, near the low end of its 5-year range (4.06%–18.80%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.90% below its 12-month average of 4.75%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.09%.
DEBT TO ASSETS RATIO
4.09%
DEBT TO ASSETS RATIO AVG TTM
4.75%
DEBT TO ASSETS RATIO AVG 3Y
10.00%
DEBT TO ASSETS RATIO AVG 5Y
11.30%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-13.90%
CURRENT VS 3Y AVG
-59.14%
CURRENT VS 5Y AVG
-63.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+4440.13%
vs the sector median at left
Xilio Therapeutics, Inc.
Market Cap
$59.83M
Debt to Assets Ratio
4.09%
TTM Avg
4.75%
3Y Avg
10.00%
5Y Avg
11.30%
Market Cap
$60.05M
Debt to Assets Ratio
0.74%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.22M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.46M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$59.00M
Debt to Assets Ratio
0.50%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.54M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$61.72M
Debt to Assets Ratio
0.59%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $59.83M | 4.09% | 4.75% | 10.00% | 11.30% |
| Fractyl Health, Inc. (GUTS)vs › | $60.05M | 0.74% | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.22M | 0.06% | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $60.46M | 0.01% | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.01M | 0.09% | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $59.00M | 0.50% | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.54M | 0.00% | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $58.21M | 0.00% | N/A | N/A | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $61.72M | 0.59% | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.93M | 0.01% | N/A | N/A | N/A |
Debt/Assets
4.1%
Debt/Equity
0.09
Current Ratio
4.25
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 4.09% |
| 2026-03-31 | 4.06% |
| 2025-12-31 | 4.50% |
| 2025-09-30 | 5.43% |
| 2025-06-30 | 5.65% |
| 2025-03-31 | 7.58% |
| 2024-12-31 | 11.46% |
| 2024-09-30 | 11.27% |
| 2024-06-30 | 9.66% |
| 2024-03-31 | 10.83% |
| 2023-12-31 | 18.80% |
| 2023-09-30 | 18.48% |
| 2023-06-30 | 18.20% |
| 2023-03-31 | 16.24% |
| 2022-12-31 | 14.33% |
| 2022-09-30 | 13.33% |
| 2022-06-30 | 11.37% |
| 2022-03-31 | 10.81% |
| 2021-12-31 | 9.36% |
| 2021-09-30 | 17.12% |
| 2021-06-30 | 14.82% |
| 2021-03-31 | 13.40% |
| 2020-12-31 | 60.26% |
